Circulating cytokines in predicting development of severe acute pancreatitis

Critical Care

Volumn 18, Issue 3, 2014, Pages

  Nieminen, Anne ^a   Maksimow, Mikael ^b,c   Mentula, Panu ^a   Kyhälä, Lea ^a   Kylänpää, Leena ^a   Puolakkainen, Pauli ^a   Kemppainen, Esko ^a   Repo, Heikki ^d   Salmi, Marko ^b,c,e  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALCIUM; COLONY STIMULATING FACTOR 1; CREATININE; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 16; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; SCATTER FACTOR; BIOLOGICAL MARKER;

ACUTE PANCREATITIS; ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CALCIUM BLOOD LEVEL; CLINICAL PRACTICE; COMORBIDITY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; HYPERCAPNIA; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RENAL REPLACEMENT THERAPY; SENSITIVITY AND SPECIFICITY; SYSTEMS BIOLOGY; ADOLESCENT; BLOOD; MIDDLE AGED; PANCREATITIS; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CYTOKINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATITIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84903942071     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13885     Document Type: Article

References (34)

1. Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsiotos GG, Vege SS, . Acute Pancreatitis Classification Working Group Classification of acute pancreatitis-2012: revision of the Atlanta classification and definitions by international consensus. Gut 2013, 62:102-111. 10.1136/gutjnl-2012-302779, 23100216, Acute Pancreatitis Classification Working Group.
2. Halonen KI, Leppaniemi AK, Puolakkainen PA, Lundin JE, Kemppainen EA, Hietaranta AJ, Haapiainen RK. Severe acute pancreatitis: prognostic factors in 270 consecutive patients. Pancreas 2000, 21:266-271. 10.1097/00006676-200010000-00008, 11039471.
3. Gloor B, Müller CA, Worni M, Martignoni ME, Uhl W, Büchler MW. Late mortality in patients with severe acute pancreatitis. Br J Surg 2001, 88:975-979. 10.1046/j.0007-1323.2001.01813.x, 11442530.
4. McKay CJ, Buter A. Natural history of organ failure in acute pancreatitis. Pancreatology 2003, 3:111-114. 10.1159/000070078, 12748419.
5. Vege SS, Gardner TB, Chari ST, Munukuti P, Pearson RK, Clain JE, Petersen BT, Baron TH, Farnell MB, Sarr MG. Low mortality and high morbidity in severe acute pancreatitis without organ failure: a case for revising the Atlanta classification to include " moderately severe acute pancreatitis." . Am J Gastroenterol 2009, 104:710-715. 10.1038/ajg.2008.77, 19262525.
6. Norman J. The role of cytokines in the pathogenesis of acute pancreatitis. Am J Surg 1998, 175:76-83. 10.1016/S0002-9610(97)00240-7, 9445247.
7. Kylänpää ML, Repo H, Puolakkainen PA. Inflammation and immunosuppression in severe acute pancreatitis. World J Gastroenterol 2010, 16:2867-2872. 10.3748/wjg.v16.i23.2867, 2887581, 20556831.
8. Buter A, Imrie CW, Carter CR, Evans S, McKay CJ. Dynamic nature of early organ dysfunction determines outcome in acute pancreatitis. Br J Surg 2002, 89:298-302. 10.1046/j.0007-1323.2001.02025.x, 11872053.
9. Johnson CD, Abu-Hilal M. Persistent organ failure during the first week as a marker of fatal outcome in acute pancreatitis. Gut 2004, 53:1340-1344. 10.1136/gut.2004.039883, 1774183, 15306596.
10. Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. Am J Gastroenterol 2006, 101:2379-2400. 10.1111/j.1572-0241.2006.00856.x, 17032204.
11. Forsmark CE, Baillie J. AGA Institute technical review on acute pancreatitis. Gastroenterology 2007, 132:2022-2044. 10.1053/j.gastro.2007.03.065, 17484894.
12. Leser HG, Gross V, Scheibenbogen C, Heinisch A, Salm R, Lausen M, Rückauer K, Andreesen R, Farthmann EH, Schölmerich J. Elevation of serum interleukin-6 concentration precedes acute-phase response and reflects severity in acute pancreatitis. Gastroenterology 1991, 101:782-785.
13. Brivet FG, Emilie D, Galanaud P. Pro- and anti-inflammatory cytokines during acute severe pancreatitis: an early and sustained response, although unpredictable of death. Crit Care Med 1999, 27:749-755. 10.1097/00003246-199904000-00029, 10321665.
14. Chen CC, Wang SS, Lee FY, Chang FY, Lee SD. Proinflammatory cytokines in early assessment of the prognosis of acute pancreatitis. Am J Gastroenterol 1999, 94:213-218. 10.1111/j.1572-0241.1999.00709.x, 9934758.
15. Mayer J, Rau B, Gansauge F, Beger HG. Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications. Gut 2000, 47:546-552. 10.1136/gut.47.4.546, 1728074, 10986216.
16. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 1995, 23:1638-1652. 10.1097/00003246-199510000-00007, 7587228.
17. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998, 17:857-872. 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E, 9595616.
18. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003, 56:1129-1135. 10.1016/S0895-4356(03)00177-X, 14615004.
19. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K, Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989, 342:440-443. 10.1038/342440a0, 2531289.
20. Aoun E, Chen J, Reighard D, Gleeson FC, Whitcomb DC, Papachristou GI. Diagnostic accuracy of interleukin-6 and interleukin-8 in predicting severe acute pancreatitis: a meta-analysis. Pancreatology 2009, 9:777-785. 10.1159/000214191, 20110745.
21. Ueda T, Takeyama Y, Toyokawa A, Kishida S, Yamamoto M, Saitoh Y. Significant elevation of serum human hepatocyte growth factor levels in patients with acute pancreatitis. Pancreas 1996, 12:76-83. 10.1097/00006676-199601000-00010, 8927623.
22. Espinosa L, Linares PM, Bejerano A, Lopez C, Sanchez A, Moreno-Otero R, Gisbert JP. Soluble angiogenic factors in patients with acute pancreatitis. J Clin Gastroenterol 2011, 45:630-637. 10.1097/MCG.0b013e31820d3533, 21750433.
23. Johnson CD, Kingsnorth AN, Imrie CW, McMahon MJ, Neoptolemos JP, McKay C, Toh SK, Skaife P, Leeder PC, Wilson P, Larvin M, Curtis LD. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut 2001, 48:62-69. 10.1136/gut.48.1.62, 1728186, 11115824.
24. Harrison DA, D'Amico G, Singer M. Case mix, outcome, and activity for admissions to UK critical care units with severe acute pancreatitis: a secondary analysis of the ICNARC Case Mix Programme Database. Crit Care 2007, 11:S1.
25. Wu BU, Conwell DL. Update in acute pancreatitis. Curr Gastroenterol Rep 2010, 12:83-90. 10.1007/s11894-010-0091-6, 20424979.
26. Oiva J, Mustonen H, Kylänpää ML, Kyhälä L, Kuuliala K, Siitonen S, Kemppainen E, Puolakkainen P, Repo H. Acute pancreatitis with organ dysfunction associates with abnormal blood lymphocyte signaling: controlled laboratory study. Crit Care 2010, 14:R207. 10.1186/cc9329, 3220021, 21087472.
27. Chakraborty S, Kaur S, Muddana V, Sharma N, Wittel UA, Papachristou GI, Whitcomb D, Brand RE, Batra SK. Elevated serum neutrophil gelatinase-associated lipocalin is an early predictor of severity and outcome in acute pancreatitis. Am J Gastroenterol 2010, 105:2050-2059. 10.1038/ajg.2010.23, 2898914, 20179686.
28. Yilmaz G, Köksal I, Karahan SC, Mentese A. The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in systemic inflammatory response syndrome. Clin Biochem 2011, 44:1227-1230. 10.1016/j.clinbiochem.2011.07.006, 21816136.
29. Moore DJ, Greystoke A, Butt F, Wurthner J, Growcott J, Hughes A, Dive C. A pilot study assessing the prognostic value of CK18 and nDNA biomarkers in severe sepsis patients. Clin Drug Investig 2012, 32:179-187. 10.2165/11598610-000000000-00000, 22217154.
30. Oiva J, Mustonen H, Kylänpää ML, Kuuliala K, Siitonen S, Kemppainen E, Puolakkainen P, Repo H. Patients with acute pancreatitis complicated by organ dysfunction show abnormal peripheral blood polymorphonuclear leukocyte signaling. Pancreatology 2013, 13:118-124. 10.1016/j.pan.2013.01.010, 23561969.
31. Skibsted S, Bhasin MK, Aird WC, Shapiro NI. Bench-to-bedside review: future novel diagnostics for sepsis-a systems biology approach. Crit Care 2013, 17:231. 10.1186/cc12693, 24093155.
32. Kylänpää-Bäck ML, Takala A, Kemppainen E, Puolakkainen P, Kautiainen H, Jansson SE, Haapiainen R, Repo H. Cellular markers of systemic inflammation and immune suppression in patients with organ failure due to severe acute pancreatitis. Scand J Gastroenterol 2001, 36:1100-1107. 10.1080/003655201750422738, 11589386.
33. Cavaillon JM, Annane D. Compartmentalization of the inflammatory response in sepsis and SIRS. J Endotoxin Res 2006, 12:151-170. 10.1179/096805106X102246, 16719987.
34. Caldwell CC, Hotchkiss RS. The first step in utilizing immune-modulating therapies: immune status determination. Crit Care 2011, 15:108. 10.1186/cc9397, 3222027, 21349138.